Treatment of hepatitis C virus infection after liver transplantation;Traitement de l'hépatite C après transplantation hépatique

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Samuel, Didier ^a   Roche, Bruno ^a   Feray, Cyrille ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; OKT 3; PLACEBO; RIBAVIRIN; TACROLIMUS;

CLINICAL TRIAL; CONFERENCE PAPER; GENOTYPE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS REPLICATION;

ACUTE DISEASE; ANIMALS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSION; INTERFERONS; LIVER TRANSPLANTATION; PAN TROGLODYTES; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRUS REPLICATION;

EID: 0036262357     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Liver transplantation in the United States from 1987-1998: Updated results from the Pitt-UNOS liver transplant registry
2. Recurrent and acquired hepatitis C viral infection in liver transplant recipients
3. Long-term outcome of hepatitis C virus infection after liver transplantation
4. Hepatitis C viral infection in liver transplant recipients
5. The course of hepatitis C infection after liver transplantation
6. Reinfection of liver graft by hepatitis C virus after liver transplantation
7. Long-term outcome of hepatitis C infection after liver transplantation
8. A longitudinal analysis of hepatitis C virus replication following liver transplantation
9. Quantification of hepatitis C virus RNA in liver transplant recipients
10. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
11. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features
12. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation
13. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia
14. Histological and clinical outcome after liver transplantation for hepatitis C
15. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
16. Hepatitis C virus genotypes and quantification of serum hepatitis C virus RNA in liver transplant recipients: Relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection
17. Hepatitis C virus genotypes in liver transplant recipients
18. The influence of hepatitis C virus genotypes on the outcome of liver transplantation
19. Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation
20. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection
21. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
22. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
23. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients
24. High incidence of post-transplant hepatitis and chronic rejection associated with hepatitis C virus infection in liver transplant recipients
25. Hepatitis C viral infection in the immunosuppressed patients
26. HCV-related fibrosis progression following liver transplantation increase in recent years
27. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C infection
28. Cholestatic hepatitis C in liver allogrefts
29. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
30. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels
31. Natural history, of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
32. Orthotopic liver transplantation for hepatitis C. Outcome, effect of immunosuppression and causes of retransplantation during an 8-year single-center experience
33. Hepatitis C infection in patients undergoing liver retransplantation
34. Retransplantation for recurrent hepatitis C
35. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years
36. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients
37. Impact of hepatitis B and C virus on kidney transplantation outcome
38. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation
39. The outcome of hepatitis C virus infection after liver transplantation. Is it influenced by the type of immunosuppression?
40. Predictors of patient and graft survival following liver transplantation for hepatitis C
41. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate
42. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation. A useful test for diagnosis of hepatitis C virus reinfection
43. Hepatitis C genotypes in liver transplant recipients: Distribution and 1-year follow-up
44. Hepatitis C virus genotypes and quantification of serum hepatitis C virus RNA in liver transplant recipients: Relationship with histologic outcome of recurrent hepatitis C
45. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: Correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns
46. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus
47. Dynamic analysis of hepatitis C virus polymorphism in patients with orthotopic liver transplantation
48. Dynamic behavior of hepatitis C virus quasispecies in patients undegoing orthotopic liver transplantation
49. Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C followng liver transplantation
50. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation
51. Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection?
52. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after transplantation for HCV cirrhosis
53. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation
54. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
55. Comparaison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
56. Impact of hepatitis G virus-coinfection on the course of hepatitis C virus infection before and after liver transplantation
57. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation
58. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C
59. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
60. Interferon alfa for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial
61. Prophylaxis against HCV recurrence after liver transplantation. Effect of interferon and ribavirin combination
62. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
63. Effect of immune globulin on prevention of experimental hepatitis C virus infection
64. An open trial of Interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
65. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen
66. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients
67. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation
68. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients
69. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation
70. Ribavirin therapy for hepatitis C infection following liver transplantation
71. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation
72. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
73. Combination of interferon alfa 2b plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study
74. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha
75. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin